-Editorials 'We, as a scienti/ic cornznity, s.hon/ld responsibly addrdess new scientific issutes by zeroing i ni on the highest priority needs with strategies that are in proportioni to the size oJthe problens. There are other sciencebased issues from the recent past that appear to be driven by debatable agendas or mandates, for example, the controversy over the use of recombinant bovine somatotropin, the continued emphasis on TCDD many years after the sources and risks of exposure were understood, the minimal response to the threat of "mad cow disease," and the failure to use mechanistic data to regulate environmental chemicals such as chloroform. Our responses to these issues have raised questions in the minds of some of our colleagues about priorities of science, communication with the public, and the relationship between research results and regulatory decisions.
threat to human health, the public is presented with confusion rather than resolution. Situations like this erode the public's confidence in our interest and ability to solve problems that, in their minds, came from the science community in the first place.
The ED issue is but one example B.A. Schwetz of a scientific strategy with mixed agendas. There are other sciencebased issues from the recent past that appear to be driven by debatable agendas or mandates, for example, the controversy over the use of recombinant bovine somatotropin, the continued emphasis on TCDD many years after the sources and risks of exposure were understood, the minimal response to the threat of "mad cow disease," and the failure to use mechanistic data to regulate environmental chemicals such as chloroform. Our responses to these issues have raised questions in the minds of some of our colleagues about priorities of science, communication with the public, and the relationship between research results and regulatory decisions.
There is increasing effort today among the federal laboratories to coordinate research directions and encourage collaboration rather than competition. Congressional appropriations targeted for specific research areas encourage more cooperation between federal agencies but restrict freedom to anticipate new problems. We need to fight the fires of the day, but still be proactive in identifying those issues that truly warrant the level of attention we have given to EDs. Rather than waiting for a public outcry to drive legislative activity, experts from federal laboratories could provide background information and perspective to members of Congress about the need (or lack thereof) for legislation related to new environmental and human health issues. Antimicrobial resistance is a problem that requires such a strategy now. A recent General Accounting Office report summarizes the background and current status of this issue (18) . There is no shortage of controversy about antimicrobial resistance, and opinions about the size of the problem range from no concern" to "major medical disaster."
As we devise strategies to resolve problems that are in the early stages of evaluation, such as the impact of antimicrobial resistance, we should heed the lessons learned from our response to the endocrine-disruptor issue and maintain a balanced approach that will maximize our efficiency and effectiveness in the future. The knowledge gained by our work as toxicologic scientists ranges from molecular mechanisms to clinical signs of toxicity, from physiologically based pharmacokinetics to tumor counts. Any of this research, from any source, may be translated into regulatory action in order to protect the public and the environment; thus, society is best served by the best science from every source. The challenge is to find the criteria to accurately and, increasingly, quickly judge which studies are valid and appropriate to affect regulation. Cynics make these quick judgments based on funding sources; traditionalists trust the proven, but slow, peer-review process; regulatory agencies want to see raw data from industry, but have implicitly trusted and exempted academia from this scrutiny. Needs for confidentiality place limits on disclosure, but they do not preclude a more even and open approach to data from all sources. Greater disclosure will result in a scientific process that is faster, better, and more trustworthy-"trust" is the key word here. But This new law has provoked, according to one editorial, "...howls of protest from scientists, their institutions, and the federal agencies that fund scientific research" (2). However, major scientific societies, including the American Chemical Society, the Council for Chemical Research, and the American Association for the Advancement of Science, all support, in principle, the need to assess the validity of such research results (3). Recently, it has again been made clear that the issues of quality and reliability of toxicology data and its reasoned interpretation for regulatory purposes are critical (4); the question is how best to accomplish that end.
Research sh3oiukld be judged oni the basis oJfstc. The tried and true way, the unfettered peer-review process, is and will continue to be the keystone of scientific pro-F gress. However, it rarely depends on the scrutiny of raw data; rather, the peer-review process _ 1 _ ultimately depends Ron R. Miller, James S. Bus, and James W. Crissman on the independent replication of important findings. Thus, it is slow, sometimes painfully so. Democracy is a similarly empirical endeavor. Like science, the process is generally ponderous and tentative, and our laws are often badly out of synchronization with science, a condition regularly exacerbated by swells of public concern. Fueled by a willing press, the public perception of a crisis can rapidly propel new regulations that may never gain a scientific foundation, nor are they repealed when science catches up. Rational or not, an alarmed public, or more often issue advocacy groups, call for immediate action well before any reasoned assessment of what action, if any, is called for. The scientific community is left unprepared. Poor decisions follow, which may have unintended consequences, levy unnecessary expense on taxpayers, and provide no demonstrable benefit for public health or the environment.
Unfortunately, as a preventative for bad regulation based on unvalidated or preliminary science, the new amendment to Circular A-1 0 is a crude vaccine that will cause more problems than it could possibly cure. The apparent intent of the law is laudable, but its shortcomings are serious: It lacks adequate protection for intellectual property, patient privacy, and against legal abuse by those who might be tempted to harass researchers with unreasonable Environmental Health Perspectives * Volume 107, Number 1 0, October 1999
